title: [The fate of children after discontinuation of treatment for acute lymphoblastic leukemia].
abstract: Among 1879 children with the diagnosis of acute lymphoblastic leukaemia made up to Dec 31 1987 in 863 cases (45.92%) treatment was discontinued. They were followed up till Dec 31 1989. The median follow-up was 3 years and 14 months. In 811 cases the treatment was discontinued during the first complete remission, in 56 cases after a relapse during initial treatment. In the time period when the programmes St. Jude and LSA2L2 were used the per cent of children with treatment withdrawal was 38.22%, but it rose to 53.01% when a more intensive programme BMF had been introduced. The probability of 7-year disease free survival after treatment discontinuation was 69.5% and 76.2% respectively. In 186 cases (21.6%) relapses developed., mostly in the first year after treatment discontinuation, but even after 7 years the risk of relapse was 2.46%. Ninety-six children (11.2%) died, 761 (88.8%) are alive, among them 671 in the first complete remission. Apart from therapy intensity, a statistically significant beneficial effect on disease free survival had discontinuation of treatment during the first complete remission, and sex--the prognosis was better in girls. In three cases secondary neoplasms were found.
authors.affiliation: Polska grupa pediatryczna ds białaczek i chłoniaków.
authors.forename: D
authors.initials: D
authors.lastname: Derulska
authors.forename: R
authors.initials: R
authors.lastname: Rokicka-Milewska
authors.forename: T
authors.initials: T
authors.lastname: Jackowska
authors.forename: J
authors.initials: J
authors.lastname: Armata
authors.forename: W
authors.initials: W
authors.lastname: Balwierz
authors.forename: J
authors.initials: J
authors.lastname: Bogusławska-Jaworska
authors.forename: A
authors.initials: A
authors.lastname: Chybicka
authors.forename: R
authors.initials: R
authors.lastname: Cyklis
authors.forename: B
authors.initials: B
authors.lastname: Darmal
authors.forename: M
authors.initials: M
authors.lastname: Jakowicka
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000209:etiology* / Q000401:mortality; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D012737:Sex Factors; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D003520:Cyclophosphamide; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin
vernacular_title: Losy dzieci po odstawieniu leczenia ostrej białaczki limfoblastycznej.